US biotech companies say gene patents not at odds with patient access
This article was originally published in SRA
Executive Summary
US biotech companies are worried that recommendations of a government task force on gene patenting and licensing, if implemented, could restrict the ability to obtain, or undermine the enforceability of, patents and exclusive licences with respect to genetic tests, according to the Biotechnology Industry Organization1,2.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.